BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc. (NASDAQ:BTAI), while maintaining a price target of $8.00. This confidence stems from the favorable trial developments for the company’s BXCL501 treatment.

The Data Safety Monitoring Board (DSMB) put forward a second positive recommendation to BioXcel Therapeutics, Inc. (NASDAQ:BTAI), allowing the company to continue its SERENITY At-Home pivotal Phase 3 safety trial without modifications. This suggestion followed a review of unblinded safety data from 178 patients dosed through May 28, 2025.

As per the research firm, SERENITY readout exhibits low risk as the main outcome is safety-based, and considering the institutional settings, IGALMI has already received approval. While the expanded label is expected to be filed by the end of this year, the firm anticipates that BioXcel Therapeutics, Inc. (NASDAQ:BTAI) will receive a label extension during the second half of 2026.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a Connecticut-based biopharmaceutical company, alongside its subsidiary, OnkosXcel Therapeutics LLC. Founded in 2017, the company employs AI to develop medicines in the areas of neuroscience and immuno-oncology.

While we acknowledge the potential of BTAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.